{
    "nct_id": "NCT04608409",
    "official_title": "A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer",
    "inclusion_criteria": "* histologically or cytologically confirmed ovarian cancer who recur within 12 months of platinum-based chemotherapy\n* ECOG performance status less than or equal to 2\n* Adequate organ and marrow function at baseline\n* ability to sign a written informed consent document\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* hypersensitivity to lapatinib or paclitaxel\n* uncontrolled intercurrent illness\n* receiving medications that inhibit or induce CYP3A4\n* malabsorption syndrome\n* congestive heart failure\n* receiving any other anti-cancer investigational agents\n* baseline neuropathy greater than Grade 1",
    "miscellaneous_criteria": ""
}